Xeris Biopharma Holdings, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Dawn Halkuff

Xeris Biopharma Holdings, Inc.’s own tally for this item (“Elect Director: Dawn Halkuff”): 62,581,577 for, 24,906,166 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each nominee was elected by a plurality vote in accordance with the Company's Amended and Restated Bylaws, as follows:”
Support: 72% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 26,424,881 for, 3,848,885 withheld, 114 abstained.

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Description as filed by funds: To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Johnson

Xeris Biopharma Holdings, Inc.’s own tally for this item (“Elect Director: John Johnson”): 52,665,077 for, 34,822,666 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each nominee was elected by a plurality vote in accordance with the Company's Amended and Restated Bylaws, as follows:”
Support: 60% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 18,447,196 for, 11,826,522 withheld, 162 abstained.

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

Xeris Biopharma Holdings, Inc.’s own tally for this item (“3. Advisory Vote to Approve Named Executive Officer Compensation”): 82,230,204 for, 4,658,035 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three: Advisory Vote to Approve Named Executive Officer Compensation The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Sec…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 60 managers: 30,298,882 for, 22,408 against, 3 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 182 managers: 38,882,932 for, 3,508,638 against, 12,251 abstained, 20,026 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Xeris Biopharma Holdings, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 125,789,818 for, 1,032,530 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 30,322,328 for, 3 against, 2 abstained.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.